Oracle Alpha’s 89bio ETNB Stock Holding History

Oracle Alpha’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$144K	Sell	12,414 -3,106	-20%	-$34.4K	0.26%	160
2023 Q4	$173K	Buy	+15,520	New	+$143K	0.22%	206

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Oracle Alpha's ETNB Position: Q1 2024 in Review

Oracle Alpha reduced its 89bio (ETNB) stake by 20% in Q1 2024, selling an estimated $34.4K and leaving 12,414 shares worth $144K. The position accounts for 0.26% of the portfolio, ranked #160.

Oracle Alpha first reported a position in ETNB in Q4 2023 and has held it in 2 quarters since. The position peaked at $173K in Q4 2023. 150 funds tracked by Wall St. Rank hold ETNB as of Q1 2024.

Oracle Alpha held 12,414 shares of 89bio worth $144K as of Q1 2024.
Oracle Alpha sold 3,106 89bio shares in Q1 2024, an estimated $34.4K.
89bio made up 0.26% of Oracle Alpha's portfolio in Q1 2024, its #160 holding.
Oracle Alpha first reported a position in 89bio in Q4 2023 and has held it in 2 quarters since.
Oracle Alpha's 89bio position peaked at $173K in Q4 2023.
150 funds tracked by Wall St. Rank held 89bio as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.